Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some pharmacology and dosing-adjacent statements (mechanism, LDL reduction concept, and starting-dose framework) align with the provided label excerpts; however, multiple claims are unsupported or not supported by the supplied label text, including the “commonly prescribed” indications framing, grapefruit/fruit-fisetin interaction, study conclusions, and patent/market status statements (not addressed in the label).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
Label Indications/Usage (1) and Mechanism of Action (12.1) indicate lipid-altering therapy and cholesterol synthesis/LDL lowering.
Lipitor works by inhibiting the production of cholesterol in the liver.
Mechanism of Action (12.1) describes LIPITOR as an HMG-CoA reductase inhibitor and cholesterol synthesis inhibition in the liver.
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
Mechanism of Action (12.1) and associated pharmacology describe reduction of LDL-C/LDL particles (e.g., “LIPITOR reduces LDL-C…”).
Unsupported Statements
Lipitor is commonly prescribed to patients with high cholesterol, heart disease, or those at risk of developing these conditions.
The provided Indications/Usage (1) states therapy is adjunctive for individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia and notes CHD or multiple risk factors for CHD, but the claim uses “commonly prescribed” and a broad disease-risk framing that is not directly supported by the provided label text.
Strawberries contain fisetin, a flavonoid that can interact with statins like Lipitor.
No label excerpt addresses strawberries, fisetin, or such a dietary component/flavonoid interaction.
Fisetin can inhibit the activity of statins like Lipitor.
No label excerpt addresses fisetin inhibiting atorvastatin/statin activity.
Inhibition of statin activity by fisetin can potentially reduce the effectiveness of Lipitor.
No label excerpt addresses fisetin or reduced effectiveness from fisetin-related inhibition.
A study in the Journal of Clinical Pharmacology found that patients who consumed high amounts of fruit and vegetables had lower levels of LDL cholesterol but required higher doses of statins to achieve the same effect.
No label excerpt discusses this specific study, “higher doses” effect, or an interaction between fruit/vegetable intake and statin dose requirements.
The patent for Lipitor (atorvastatin) expired in 2011, allowing generic versions of the medication to enter the market.
Patent/market status is not addressed in the provided prescribing information excerpts.
The patent for the combination of atorvastatin and fenofibrate is still in effect.
Patent/market status for the combination is not addressed in the provided prescribing information excerpts.
Contradictions
Important Omissions
If the intent is to support drug-drug/diet interactions, the label excerpt specifically addresses grapefruit juice and lists risk-increasing coadministration with strong CYP3A4 inhibitors, cyclosporine, fibric acid derivatives, and lipid-modifying doses of niacin. None of these were discussed by the AI claims.
Importance:
Moderate
The label includes specific dosing recommendations (starting dose 10 or 20 mg once daily; up to 10–80 mg once daily; timing with/without food; lipid levels check in 2–4 weeks). No AI claim provided dosing details to evaluate against this label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The most safety-relevant issues (interactions) were addressed with unsupported claims about fisetin/strawberries and a study-driven dose adjustment narrative; the label excerpt provided instead emphasizes grapefruit juice and certain interacting agents. Unsupported interaction claims could mislead interpretation of effectiveness/safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Unsupported interaction and external non-label claims (fisetin/strawberries, fruit/vegetable study dose-effect, and patent/market status) that are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit interaction statements to what the label excerpt supports (e.g., grapefruit juice >1.2 L/day and coadministration with strong CYP3A4 inhibitors/other listed agents). Remove patent/market and study-specific claims unless the provided prescribing information contains them.